BIIB - too early to catch it

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases. It has very strong fundamentals: Net Margin 43.8%, Return on Capital 138% and its relatively cheap traded at 12.3 x Price-to-Free-Cash-Flow.

This morning BIIB dropped by 27% at open. Despite the fact that its a great company with attractive valuation I would NOT buy it here. The move down off the top at 480.18 reached in March 2015 looks like a classic corrective (A)-(B)-(C) down structure. The final wave (C) down should stretch at least to 76.4% extension of the first leg down in wave (A) that bottomed at 223.02 in July 2016. When price gets to 192 or lower in a move down with a clear five wave structure I would be interested in buying that stock.

BIIB - weekly chart updated on 3/18/2019

Start to Learn Now!

Subscribe to my video course
and learn to predict market moves

Check My Latest Updates!

Get all the updates on one screen
and filter out only symbols you need

Login